Mavoglurant is under clinical development by Stalicla and currently in Phase II for Alcohol Dependence. According to GlobalData, Phase II drugs for Alcohol Dependence does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Mavoglurant LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mavoglurant overview
Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is administered orally. It targets a metabotropic glutamate receptor 5 (mGluR5).
It was also under development for the treatment of the obsessive compulsive disorder (OCD), chorea in Huntington's disease, moderate to severe L-dopa induced dyskinesia, gastroesophageal reflux disease and smoking cessation.
Stalicla overview
Stalicla is a biotechnology company developing precision medicine treatments for patients with Neurodevelopmental disorders. Stalicla is headquartered in Geneva, Switzerland.
For a complete picture of Mavoglurant’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
